Oniria Therapeutics Analysis

Treat cancer patients with recurrent tumors; Overcome drug resistance in cancer therapies; Prolong patient survival through innovative treatments; Exploit vulnerabilities in dormant cancer cells; Develop precision medicine for cancer treatment.

Supported by VHIO, UB, and ICREA; Received funding from European Union initiatives; Focused on developing precision drugs for cancer treatment.

Main Information

• Information: Oniria Therapeutics is dedicated to solving cancer persistence by bringing to market ONR-001, a first-in-class drug for treating aggressive solid and liquid tumors that are unresponsive to current treatments. The company is currently characterizing its final candidate and preparing for the regulatory preclinical phase.
• Interests: HEALTH/FITNESS/WELLBEING, IMPACT/SOCIAL INNOVATION
• Location: Hall 8.1 - 4YFN Stand 8.1C23.1A
• Tagged as startup: Yes

Contact & Links

• LinkedIn: Connect on LinkedIn
• Twitter: Follow on X (formerly Twitter)
• Phone Number: +34 620006316
• Email: Email

Key Information

• Growth Stage: Series A
• Country: Spain
• Founding Year: 2021

Company Context

• Company Name: Oniria Therapeutics
• Company Website: https://www.oniriatherapeutics.com/